BTIG lowered its price target for IMV (NASDAQ, TSX:IMV) to $5 from $8, citing uncertainty about data from the company’s ongoing Phase 2 study of DPX-Survivac in patients with advanced recurrent ovarian cancer. The stock...
Tag - DPX-Survivac
